Alvotech and Advanz Pharma have expanded their collaboration to include the supply and commercialisation of Alvotech’s biosimilar candidate AVT10 in Europe.
AVT10 is a biosimilar candidate to Cimzia (certolizumab pegol), a TNF-alpha inhibitor intended to treat various inflammatory diseases.
The expanded partnership marks a significant step in their ongoing partnership, which already covers over ten reference biologics.
Alvotech, a biotech company based in Luxembourg, focuses on developing and manufacturing biosimilar medicines globally.
With a pipeline of eight disclosed biosimilar candidates, Alvotech aims to address autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
The company has established strategic partnerships to extend its reach in markets including China, Europe, Japan, the Middle East, South America, and the US.
Alvotech Chairman and CEO Róbert Wessman said: “Our biosimilar candidate is the only one referencing Cimzia that is under development globally, and the reference product has carved out a significant market share as a treatment for chronic rheumatic diseases, especially for women of childbearing age.
“I’m very pleased to add it to our expanding commercial partnership with Advanz Pharma.”
Based in London, UK, Advanz Pharma is committed to enhancing patient care through speciality, hospital, and rare disease medicines.
The company operates in over 90 countries, with a direct presence in more than 20, including Australia, Canada, Europe, and the US.
Advanz Pharma’s portfolio includes innovative medicines, biosimilars, speciality generics, and originator brands across various therapeutic areas.
Advanz Pharma CEO Steffen Wagner said: “This agreement further strengthens our strategic partnership with Alvotech and supports our goal to expand access to high-quality biologics for patients in Europe.
“A proposed biosimilar to Cimzia is a valuable addition to our sizable biosimilars pipeline.”
In May 2025, the partnership between Alvotech and Advanz Pharma was further expanded to cover three additional biosimilar candidates for the European market.
The partnership includes biosimilars to Ilaris (canakinumab), Kesimpta (ofatumumab), and an undisclosed early-stage candidate.
Alvotech is responsible for managing development and commercial supply, while Advanz Pharma will oversee registration and commercialisation in Europe.
The expanded partnership involves development and commercial milestones valued at up to $180m, alongside a revenue-sharing arrangement.
Alvotech and Advanz Pharma are expected to launch their first biosimilars in Europe by the fourth quarter of 2025.
